Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of Insulin Analogues
27-Nov-2008 -
Merrion Pharmaceuticals and Novo Nordisk A/S have entered into a Development and License Agreement to develop and commercialise oral formulations of Novo Nordisk's proprietary Insulin analogues, using Merrion's proprietary GIPET(r) technology. Under the agreement Merrion will receive up to US$58 ...
biopharmaceuticals
insulin
license agreements
+2